Literature DB >> 23183350

Gender-specific differences in major cardiac events and mortality in lamin A/C mutation carriers.

Ingrid A W van Rijsingen1, Eline A Nannenberg, Eloisa Arbustini, Perry M Elliott, Jens Mogensen, Johanna F Hermans-van Ast, Anneke J van der Kooi, J Peter van Tintelen, Maarten P van den Berg, Maurizia Grasso, Alessandra Serio, Sharon Jenkins, Camilla Rowland, Pascale Richard, Arthur A M Wilde, Andreas Perrot, Sabine Pankuweit, Aeilko H Zwinderman, Philippe Charron, Imke Christiaans, Yigal M Pinto.   

Abstract

AIMS: Mutations in the lamin A/C gene (LMNA) cause a variety of clinical phenotypes, including dilated cardiomyopathy. LMNA is one of the most prevalent mutated genes in dilated cardiomyopathy, and is associated with a high risk of arrhythmias, sudden cardiac death, and heart failure. There are few data on the impact of age and gender on cardiac disease penetrance and mortality. METHODS AND
RESULTS: In a multicentre cohort of 269 LMNA mutation carriers, we evaluated gender-specific penetrance of cardiac involvement and major cardiac events. All-cause mortality of mutation carriers [standardized mortality ratio (SMR)] was determined. Cardiac disease penetrance was age dependent and almost complete at the age of 70 years. The presence of an LVEF ≤45% was significantly higher in men (P < 0.001). However, there was no difference between genders in the prevalence of atrioventricular block, atrial tachyarrhythmias, and non-sustained ventricular tachycardia. Malignant ventricular arrhythmias (26% vs. 8%) and end-stage heart failure (28% vs. 14%) were more common in men than in women (P < 0.001 and P = 0.006, respectively). All-cause mortality of mutation carriers was significantly increased [SMR 4.0, 95% confidence interval (CI) 2.8-5.2] between the ages of 15 and 75 years. Mortality in men was higher than in women (hazard ratio 2.2, 95% CI 1.2-4.3).
CONCLUSIONS: This large cohort of LMNA mutation carriers demonstrates a high cardiac disease penetrance and a high mortality in mutation carriers. Male mutation carriers have a worse prognosis due to a higher prevalence of malignant ventricular arrhythmias and end-stage heart failure.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23183350     DOI: 10.1093/eurjhf/hfs191

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  40 in total

Review 1.  Genetic Variation in Cardiomyopathy and Cardiovascular Disorders.

Authors:  Elizabeth M McNally; Megan J Puckelwartz
Journal:  Circ J       Date:  2015-06-04       Impact factor: 2.993

Review 2.  Molecular genetics and pathogenesis of cardiomyopathy.

Authors:  Akinori Kimura
Journal:  J Hum Genet       Date:  2015-07-16       Impact factor: 3.172

3.  Variant Interpretation for Dilated Cardiomyopathy: Refinement of the American College of Medical Genetics and Genomics/ClinGen Guidelines for the DCM Precision Medicine Study.

Authors:  Ana Morales; Daniel D Kinnamon; Elizabeth Jordan; Julia Platt; Matteo Vatta; Michael O Dorschner; Carl A Starkey; Jonathan O Mead; Tomohiko Ai; Wylie Burke; Julie Gastier-Foster; Gail P Jarvik; Heidi L Rehm; Deborah A Nickerson; Ray E Hershberger
Journal:  Circ Genom Precis Med       Date:  2020-03-11

4.  Assessment of fibroblast nuclear morphology aids interpretation of LMNA variants.

Authors:  Florence H J van Tienen; Patrick J Lindsey; Miriam A F Kamps; Ingrid P Krapels; Frans C S Ramaekers; Han G Brunner; Arthur van den Wijngaard; Jos L V Broers
Journal:  Eur J Hum Genet       Date:  2018-11-12       Impact factor: 4.246

5.  Genetic basis and molecular biology of cardiac arrhythmias in cardiomyopathies.

Authors:  Ali J Marian; Babken Asatryan; Xander H T Wehrens
Journal:  Cardiovasc Res       Date:  2020-07-15       Impact factor: 10.787

Review 6.  Lamin A/C Cardiomyopathies: Current Understanding and Novel Treatment Strategies.

Authors:  Xi Wang; Allyson Zabell; Wonshill Koh; W H Wilson Tang
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-03

Review 7.  Where genotype is not predictive of phenotype: towards an understanding of the molecular basis of reduced penetrance in human inherited disease.

Authors:  David N Cooper; Michael Krawczak; Constantin Polychronakos; Chris Tyler-Smith; Hildegard Kehrer-Sawatzki
Journal:  Hum Genet       Date:  2013-07-03       Impact factor: 4.132

8.  Elevated dual specificity protein phosphatase 4 in cardiomyopathy caused by lamin A/C gene mutation is primarily ERK1/2-dependent and its depletion improves cardiac function and survival.

Authors:  Jason C Choi; Wei Wu; Elizabeth Phillips; Robin Plevin; Fusako Sera; Shunichi Homma; Howard J Worman
Journal:  Hum Mol Genet       Date:  2018-07-01       Impact factor: 6.150

9.  Lamin A mutation impairs interaction with nucleoporin NUP155 and disrupts nucleocytoplasmic transport in atrial fibrillation.

Authors:  Meng Han; Miao Zhao; Chen Cheng; Yuan Huang; Shengna Han; Wenjuan Li; Xin Tu; Xuan Luo; Xiaoling Yu; Yinan Liu; Qiuyun Chen; Xiang Ren; Qing Kenneth Wang; Tie Ke
Journal:  Hum Mutat       Date:  2018-12-08       Impact factor: 4.878

10.  Plasma microRNAs as biomarkers for Lamin A/C-related dilated cardiomyopathy.

Authors:  Rocío Toro; Sara Blasco-Turrión; Francisco José Morales-Ponce; Pablo Gonzalez; Pablo Martínez-Camblor; Amador López-Granados; Ramon Brugada; Oscar Campuzano; Alexandra Pérez-Serra; Felix Rosa Longobardo; Alipio Mangas; Vicenta Llorente-Cortes; David de Gonzalo-Calvo
Journal:  J Mol Med (Berl)       Date:  2018-07-14       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.